HomeAI · summaries
Storia in 3 fonti
BioNTech Stock Dips After BNT122-01 Trial Termination - BioNTech (NASDAQ:BNTX)
BioNTech shares are dropping Friday after the company decided to end its Phase 2 trial of autogene cevumeran in resected colorectal cancer.
Confronto fonti
3 prospettive sulla stessa storiaTimeline cronologica
- ·
endpoints.news
BioNTech, Genentech terminate Phase 2 of personalized mRNA cancer vaccine
BioNTech said Friday that it ended a mid-stage trial that was testing autogene cevumeran as an adjuvant monotherapy in certain colorectal cancer patients.
- ·
benzinga.com
BioNTech Stock Dips After BNT122-01 Trial Termination - BioNTech (NASDAQ:BNTX)
BioNTech shares are dropping Friday after the company decided to end its Phase 2 trial of autogene cevumeran in resected colorectal cancer.
